Sonneveld P, Schmidt-Wolf IG, Van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phaseⅢ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30(24): 2946-2955.
Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study[J]. Lancet, 2010, 376(9758): 2075-2085.
Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study[J]. Cancer, 2010, 116(13): 3143-3151.
Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phaseⅢ trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.